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Most spine fusion procedures involve the use of prosthetic fixation devices combined with autologous bone
grafts rather than biological treatment. We had shown that spine fusion could be achieved by injection of bone
morphogenetic protein-2 (BMP-2)-expressing mesenchymal stem cells (MSCs) into the paraspinal muscle. In this
study, we hypothesized that posterior spinal fusion achieved using genetically modified MSCs would be me-
chanically comparable to that realized using a mechanical fixation. BMP-2-expressing MSCs were injected
bilaterally into paravertebral muscles of the mouse lumbar spine. In one control group BMP-2 expression was
inhibited. Microcomputed tomography and histological analyses were used to evaluate bone formation. For
comparison, a group of mouse spines were bilaterally fused with stainless steel pins. The harvested spines were
later tested using a custom four-point bending apparatus and structural bending stiffness was estimated. To
assess the degree to which MSC vertebral fusion was targeted and to quantify the effects of fusion on adjacent
spinal segments, images of the loaded spine curvature were analyzed to extract rigidity of the individual spinal
segments. Bone bridging of the targeted vertebrae was observed in the BMP-2-expressing MSC group, whereas
no bone formation was noted in any control group. The biomechanical tests showed that MSC-mediated spinal
fusion was as effective as stainless steel pin-based fusion and significantly more rigid than the control groups.
Local analysis showed that the distribution of stiffness in the MSC-based fusion group was similar to that in the
steel pin fusion group, with the majority of spinal stiffness contributed by the targeted fusion at L3–L5. Our
findings demonstrate that MSC-induced spinal fusion can convey biomechanical rigidity to a targeted segment
that is comparable to that achieved using an instrumental fixation.
Introduction
Low back pain is the most common cause of disability inpeople younger than 45 years. It accounts for 8 million
physician visits and 89million lost work days per year,1 and it
incurs an estimated cost of up to $50 billion annually.2 Low
back pain is caused by intervertebral disc degeneration and
other pathological conditions such as spondylosis, scoliosis,
spondylolisthesis, tumor, infection, and posttraumatic frac-
ture.3 Fusion of two or more adjacent vertebrae is commonly
performed to treat these debilitating conditions, and>250,000
such procedures are performed annually in the United States
alone.4 The complication rates in these procedures, although
low, increase with patient age and reach 12% in patients older
than 75 years.5 Procedures involving the application of bone
grafts harvested from the iliac crest reportedly lead to adverse
complications in 10%–35% of cases.6,7 Another widely used
treatment includes the implantation of metal cages containing
recombinant bone morphogenetic protein-2 (BMP-2). High-
dose recombinant human BMP-2 (rhBMP2) has been found to
cause pseudarthroses,8,9 various infections,10 ectopic bone
formation that cause neural compression,11 and abdominal
bone growth.12 In osteoporotic compression fractures of the
spine, the use of instrumental fixation to achieve spinal fusion
has a high failure rate due to low bone mass; when this pro-
cedure is combined with vertebral augmentation involving
biomaterials such as poly(methyl methacrylate) (PMMA), a
significant modulus mismatch with adjacent vertebrae
may occur, leading to increased stress at the augmented–
nonaugmented junction.13
Efforts have been made to develop an injectable biological
agent that would induce spine fusion without the need for
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bone grafts and synthetic implants. Such a solution would
avoid open surgery and lengthy hospitalization, which is lar-
gely responsible for the high costs of treating lower back
pain.14 It would also reduce the risks of open surgery, such as
respiratory and cardiac complications, because such an injec-
tion can be given using a local anesthetic agent. Finally, if fu-
sion is not achieved, additional injections can be administered
without subjecting the patient to multiple surgical procedures.
Direct delivery of osteogenic genes to induce spine fusion
has been described in several studies.4,15 Another attractive
biological approach used to induce fusion includes the in-
jection of genetically modified mesenchymal stem cells
(MSCs).16–19 We previously demonstrated that MSCs over-
expressing a BMP gene could be effectively used to induce
spine fusion in a mouse model.20,21 The BMP gene can be
introduced into a cell in a variety of ways, including viral22,23
and nonviral methods.21,24 MSCs can be isolated from vari-
ous adult tissues, such as bone marrow and adipose tissue,25
following common procedures such as liposuction.
We have explored structural,20,21 nanomechanical, and
nanostructural properties of bone tissue induced by en-
gineered MSCs, and showed that intrinsic biomechanical
properties may depend on the injection site.26,27 However, to
date, no one has reported whether the bone mass generated
by engineered MSCs can indeed lead to mechanical stabili-
zation, which is the prime goal of spine fusion.
In this study we injected BMP-2-engineered MSCs into the
paraspinal muscles of mice to achieve lumbar spine fusion.
Five weeks after injection, at which point prominent bone
masses had formed, we tested the bending rigidity of the
fused lumbar spines and compared our findings with those
in spines fused with stainless steel pins or injected with
MSCs that did not express BMP-2.28 We also analyzed the
structural properties of the newly formed bone using mi-
crocomputed tomography (mCT). Our results indicated that
MSC-mediated spinal fusion was as rigid as stainless steel
pin-based fusion and was significantly more rigid than any
fusion attained in the control groups. Interestingly, these
mechanical results were achieved even though the newly
formed bone had lower bone volume density and mineral
density than the host vertebrae. Finally, by performing an
immunohistochemical analysis we were able to identify im-
planted MSCs in the new bone that fused the vertebrae.
This is the first report demonstrating that injections of
BMP-2-engineered MSCs can lead to biomechanically robust
spine fusion. The results of this study constitute another step
toward a novel biological solution for the minimally invasive
treatment of lower back pain.
Materials and Methods
Generation of a genetically engineered MSC line
Genetic engineering of MSCs to express BMP-2 in a
doxycycline (DOX)-inducible system has been described
elsewhere.28 Briefly, cells from the C3H10T1/2 MSC line
were transfected with a ptTATop-BMP-2 plasmid vector that
encodes for both the tetracycline transactivator and BMP-2
cDNAs. In addition, the cells were infected with a retrovirus
encoding for the b-galactosidase (b-Gal) reporter gene, as
previously reported,28 so that we could track the cells in situ.
Expression of BMP-2 can be shut off in the presence of DOX,
a homolog of tetracycline, or turned on in DOX’s absence.
We previously showed that this MSC line is capable of in-
ducing bone formation in ectopic and orthotopic implanta-
tion sites.20,28
Cell culture
Cells were cultured in 140-mm culture plates in a complete
growth medium (Dulbecco’s modified Eagle’s medium con-
taining 10% fetal bovine serum, 2mM L-glutamine, 100U/
mL penicillin, and 100U/mL streptomycin; Biological In-
dustries, Beit Haemek, Israel) in a 5% CO2/95% air atmo-
sphere at 378C. DOX (1 mg/mL) was added to the medium to
prevent cell differentiation before implantation. Before the
in vivo studies commenced, the cells were trypsinized and
centrifuged at 300 g and 48C for 5min. The cells were
counted using the Trypan blue exclusion test and separated
into aliquots of 5106 cells.
In vivo cell injection
All procedures used in this study were approved by
the Hebrew University institutional animal care and use
committee. Cohorts of 10-week-old female C3H/HeN mice
were anesthetized by intraperitoneal injection of a xylazine–
ketamine mixture (3.3mg/kg xylazine and 100mg/kg keta-
mine). Aliquots of 5106 MSCs were suspended in 50mL
fibrin gel (Tisseel; Baxter, Vienna, Austria) and injected into
the lumbar paravertebral muscle in a manner previously
described20,21 and illustrated in Figure 1. Each mouse re-
ceived two injections, one injection on each side. The ex-
perimental group (nine mice), denoted as the MSC/DOX
group, received injections of BMP-2-expressing MSCs fol-
lowed by a normal diet of food and water. The control cohort
(seven mice), denoted as the MSC/þDOX group, also re-
ceived injections of BMP-2-expressing MSCs but were given
DOX in their drinking water (0.5mg/mL) to shut off BMP-2
expression. Another control group (seven mice), known as
the FG Only group, received injections containing only fibrin
gel. The mice were housed in a specific pathogen-free animal
facility. After 5 weeks the mice were euthanized by an
overdose of pentobarbital (120mg/kg i.p.) after which their
FIG. 1. This diagram demonstrates the site and the direc-
tion of the stem cell injection to the paraspinal muscle in
lateral (A) and posterior (B) view. Orange color represents
the new bone formation in the site of stem cells injection.
Color images available online at www.liebertonline.com/
ten.
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spines were harvested, wrapped in saline-soaked gauze, and
frozen in 208C. Some spines were stored without fixation in
208C, thawed for a few hours in phosphate-buffered saline
(PBS) for mCT scanning, and frozen again until subjected to
biomechanical tests. Other spines destined for histological
analysis were fixed in 4% formalin.
Microcomputed tomography
To evaluate volumes of bone formation and structural
parameters, each spine was scanned using a desktop cone-
beam mCT scanner (mCT 40; Scanco Medical AG, Bassersdorf,
Switzerland). Micro-tomographic slices were acquired at
1000 projections and reconstructed at a spatial nominal res-
olution of 16 mm. Newly formed bone was separated from
native bone by manual contouring. As a reference for mature
native bone, we used posterior portions of mouse lumbar
vertebrae contoured in the same manner (Native Spine
group). Using direct three-dimensional (3D) morphometry
for newly formed bone and control tissue, we determined the
following morphometric indices: (a) total bone volume (TV)
in cubic millimeters, which included bone and soft tissue
regions; (b) volume of mineralized bone tissue (BV) in cubic
millimeters; (c) bone volume density (BVD), which was cal-
culated as the BV/TV ratio; (d) bone mineral density (BMD;
mg hydroxyapatite (HA)/cm3) derived from the projectional
image and calculated based on calibration with commercially
available Micro-CT phantom containing H2KPO4 (Scanco
Medical AG); (e) average bone thickness (BT) in millimeters;
(f) degree of anisotropy (DA), which was determined from
the ratio of maximal to minimal radii of the mean intercept
length of the ellipsoid; and (g) connectivity density (Conn-Den;
mm3).29,30 The extent of the fusion and the number of ver-
tebrae that were fused were determined manually by ex-
amining coronal and lateral sections of 3D images.
Biomechanical assays
Mouse spine preparation. All muscle and soft tissue
surrounding the spines were removed, taking care to leave
the joint capsules and spinal ligaments intact. To simulate the
posterolateral spinal fusion that can be achieved using metal
implants, the spines of seven 10-week-old C3H/HeN mice
were fixed bilaterally between L-3 and L-5 by using 0.8-mm
stainless steel pins. Additional specimens (n¼ 7) were col-
lected and tested as intact spines (Native Spine group).
Assessing lumbar spine rigidity in four-point bend-
ing. Loading assays were performed on an L2–6 segment
for all groups, the analog of the human L1–5 segment. To
determine the parameters for testing, intact spines were
nondestructively tested using a custom-made four-point
bending apparatus and a universal test machine (Zwick
1456, Ulm, Germany). As the extremely low bending stiffness
of the normal murine spine precluded the use of potting
materials, we relied only on the natural curvature of the
spine and gravity to mount specimens within the test ap-
paratus. The exterior support span was set to 15.3mm, thus
supporting the L6–S1 and L1–L2 junctions. An interior sup-
port span of 4.5mm was centered with respect to the outer
span. Spines were subjected to five loading cycles of 0.40N at
a rate of 0.10N/s, which resulted in an approximate bending
moment of 1.1N mm. Load–displacement data from the final
cycle and the test geometry were then used to generate an
approximate structural bending stiffness (elastic modulus
multiplied by area moment of inertia [EI]).31,32
Assessing local rigidity of fused and adjacent seg-
ments. A localized analysis of bending stiffness in indi-
vidual spine segments was performed by analyzing
moment-induced changes in the spine’s radius of curvature.
Four-point bending was performed, as described earlier,
while obtaining lateral images of the spine with the aid of a
high-resolution digital video camera (Basler A602f, Ahrens-
burg, Germany). Semiautomated image postprocessing was
implemented to detect the contour of the anterior spine and
to fit a fourth-order polynomial curve to the contour. The
bending stiffness of a designated section of the lumbar spine
was then derived from the applied bending moment and the
radius of the segment curvature.33
Histological analysis
Harvested specimens were fixed in 4% formalin for 24 h,
decalcified by soaking in 0.5M ethylenediaminetetraacetic
acid solution (pH¼ 7.4) for 2 weeks, and dehydrated by
passing through an increasing-grade series of ethanol baths,
and embedded in paraffin. Five-micron-thick sections were
cut from each paraffin block with the aid of a motorized
microtome (Leica Microsystems, Nussloch, Germany). He-
matoxylin and eosin (H&E) and bone matrix-specific Masson
trichrome stain were applied to tissue sections as previously
reported.34
Immunohistochemical staining for b-galactosidase
An immunohistochemical assay (HISTOSTAIN KIT, Cat-
alog No. 956143; Zymed Laboratories, South San Francisco,
CA) was performed on paraffin sections of fused spines to
detect expression of the b-Gal reporter gene by the en-
gineered MSCs.28 Sections of tissue were deparaffinized by
applying xylene, rehydrated by bathing in a descending-
grade series of ethanol, and rinsed with double distillered
water (DDW). Endogenous peroxidase activity was removed
by treatment with 0.1% H2O2. A primary antibody that reacts
with rabbit b-Gal (ab616-100; Abcam, Cambridge Science
Park, Cambridge, United Kingdom) was diluted 1:750 in 3%
PBS/bovine serum albumin and applied to the slides for 1 h
at room temperature. After incubation with the primary an-
tibody, the slides were rinsed in PBS and a secondary rabbit
anti-mouse immunoglobulin G-antibody (biotin-conjugated;
Zymed Laboratories) was applied to the slides at room
temperature for 30min. After they had been washed with
PBS, the slides were incubated with horseradish peroxidase
conjugated to streptavidin and then stained with 3-amino-9-
ethylcarbazole dye. The slides were counterstained with
hematoxylin, washed, mounted with GVA (Zymed Labora-
tories), and observed with the aid of light microscopy.
Statistical analysis
All mean values in the Results section and figures are
displayed with their standard errors. Statistical tests for
significance were performed using the two-tailed Student’s
t-test, and the minimal criterion for significance was deter-
mined to be a probability level <0.05.
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Results
mCT-based analysis of newly formed spine fusion
In this study MSCs that had been genetically engineered to
express BMP-2 were suspended in fibrin gel, and the sus-
pension was then injected into the paravertebral muscles of
10-week-old C3H/HeN mice to achieve posterolateral spinal
fusion. Five weeks after injection, the mouse spines were
harvested and evaluated using mCT. New bone formation
was evident in all mice that received MSCs, but no DOX was
added to their drinking water (MSC/DOX group). No
bone formation was detected in the control groups (MSC/
þDOX and FG Only groups); thus, complete mCT analysis
was only undertaken for the MSC/DOX group. Results
showed that an intervertebral bridge of new bone mass had
formed (Fig. 2), fusing 2.4 0.4 vertebrae per injection
(n¼ 18) and 3.1 0.6 vertebrae per mouse (n¼ 9). The sites of
fusion between the new bone mass and the native vertebrae
numbered 2.3 0.4 per injection (n¼ 18). All counts of fusion
sites were made by evaluating 3D images and confirmed by
evaluating two-dimensional images. The new bone mass
formed along the spine, spanning adjacent segments; how-
ever, not all segments were fused (Fig. 2).
To evaluate the structural parameters of the newly formed
bone masses, we compared them with posterior portions of
intact native vertebrae (Fig. 3). In the MSC/DOX group the
TV of newly formed bone (which includes cavities in the
tissue) was 132.5 8.4mm3 (n¼ 9), and the actual bone
volume (BV) for the newly formed mass was 44.7 3.7mm3.
The BVD (calculated as BV/TV) in the MSC/DOX group
FIG. 2. Spinal fusion imaging
using mCT. Mouse spines were
harvested 5 weeks after MSCs
genetically engineered to express
BMP-2 were injected bilaterally
into the paravertebral muscles.
New bone mass was contoured
manually and is represented by
the orange regions in the 3D im-
ages (B, D). Yellow arrows in-
dicate fusion sites (A–G). Sagittal
(A, B), coronal (C, D), and lateral
(E) 3D reconstructed image of a
representative spine were made
using Scanco software. Axial
sections of the spine are shown in
2D (F) and 3D (E) images. mCT, microcomputed tomography; MSC, mesenchymal stem cells; BMP-2, bone morphogenetic
protein-2; 3D, three-dimensional. Color images available online at www.liebertonline.com/ten.
FIG. 3. Quantitative mCT analysis of new bone structural properties (MSC/DOX group) compared to the posterior
portions of intact vertebrae (Native Spine group). (A) mCT reconstructed images. (B–F) Graphs showing bone structure
parameters: bone volume density calculated as the ratio between bone volume and total tissue volume (B); bone mineral
density (C); average bone thickness (D); connectivity density (E); and degree of anisotropy (F). Bars indicate SE, *p< 0.05.
MSC/DOX group n¼ 9; Native Spine group n¼ 3. DOX, doxycycline; SE, standard error; HA, hydroxyapatite.
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was 0.34 0.02, whereas that in the control vertebrae (Native
Spine group) was much higher: 0.77 0.03 (n¼ 3, p< 0.05).
The BMD in the MSC/DOX group was 663 16mg HA/
cm3 (n¼ 9), whereas the BMD in the Native Spine group was
880 35mg HA/cm3 (n¼ 3, p< 0.05). The average BT pa-
rameter indicates the solidness of newly formed bone.29 The
average thickness of newly formed bone in the MSC/DOX
group was 0.13 0.01mm (n¼ 9); the average thickness of
the control vertebrae (Native Spine Group) was slightly
higher, 0.17 0.01mm (n¼ 3), but the difference was not
statistically significant. The parameter of Conn-Den is used
to evaluate to what degree the bone is branched and porous
at its structure. The fusion mass in the MSC/DOX group
had a Conn-Den value of 56.1 3.7mm3 (n¼ 9), whereas
the control vertebrae (Native Spine group) had a value of
only 27.3 1.5mm3 (n¼ 3, p< 0.05). There was no signifi-
cant difference between the MSC/DOX group and the
Native Spine group with respect to the DA, another struc-
tural parameter. In the MSC/DOX group the DA in the
fusion mass was 1.58 0.02 (n¼ 9), and in the Native Spine
group it was 1.47 0.05 (n¼ 3).
Biomechanics of spine fusion
To evaluate the segmental stabilization achieved by pos-
terolateral spinal fusion using genetically engineered MSCs,
biomechanical loading tests were performed. We performed
loading tests on spines harvested from 10-week-old C3H/
HeN mice that had undergone different treatments—injections
of BMP-2-expressing MSCs with no DOX added (MSC/
DOX group); spinal fusion performed using stainless steel
pins bilaterally through L3–L5 (SSP group); injections of BMP-
2-expressing MSCs with the addition of DOX (MSC/þDOX
control group); injections of fibrin gel withoutMSCs (FGOnly
control group)—or on intact native spines (Native Spine
group) (Fig. 4A). The two first groups (containing nine and
seven mice, respectively) shared similar values of spinal ri-
gidity and high values of spinal bending modulus (EI, in N/
mm3), which were significantly higher than values found in
the control groups (Fig. 4B). The rigidity parameters of each
control groupwere similar to those in the Native Spine group.
To determine which region of the spine contributed the
most to rigidity of the lumbar segment, the distribution of
spinal stiffness between different spine levels was quantified
(Fig. 5). In spines fused using MSCs the majority of spinal
stiffness came from the L3–L5 segment, whereas the other
segments (L2–L3 and L5–L6) showed little contribution. As
expected, similar results were seen in spines fused using
stainless steel pins, with the majority of the stiffness oriented
in L3–L5 fused segments. The distribution of stiffness in
native spines was much more evenly dispersed (Fig. 5).
Histological analysis
Standard H&E and bone matrix-specific Masson trichrome
stains were applied to tissue to examine the morphological
characteristics of the newly formed bone masses. The histo-
logical sections demonstrated a large area of endochondral
bone formation containing a focus of cartilage surrounded by
new bone trabeculae. Areas containing bone marrow were
evident as well. The new bone tissue was fused to the pos-
terolateral aspect of the mouse vertebrae (Fig. 6A, B).
Contribution of engineered MSCs
to new bone formation
An immunohistochemical assay for detection of cells that
express b-Gal was performed to evaluate the contribution of
FIG. 4. Lumbar spine rigidity evaluated by opto-mechanical
tests. (A) Native murine spine subjected to loading tests (on
the left) and an image of fused murine spine using bilateral
stainless steel is shown on the right. (B) Lumbar spine ri-
gidity comparison is shown for spines groups with different
treatments. Bars indicate SE (n¼ 7 in each group). SSP group:
spinal fusion performed using stainless steel pins; FG Only
group: control group received injections containing only fi-
brin gel. *p< 0.05.
FIG. 5. Segment contributions to total lumbar spine rigid-
ity. Distribution of spinal rigidity is shown for the following
segments of the lumbar spine: L1–2, L2–4, and L4–5. The
rigidity of each segment is normalized for the rigidity of
the entire lumbar spine and shown in percentages. The
distribution of rigidity is shown for spines after injection of
MSCs genetically engineered to express bone morphoge-
netic protein-2 (MSC/DOX group); SSP group, and native
spines. Vertical bars indicate SE (n¼ 7 in all group). Hor-
izontal lines indicate significant differences (spinal fusion
performed using stainless steel pins; p< 0.05).
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genetically engineered MSCs to newly formed bone mass
and resulting spinal fusion. The immunohistochemical find-
ings showed that the newly formed bone contained numer-
ous b-Gal-labeled MSCs (Fig. 6C). Positive staining appeared
mainly in hypertrophic chondrocytes and in osteocytes em-
bedded in the new bone tissue. No staining for b-Gal was
visible in the native vertebra (Native Spine group), except at
the site of fusion.
Discussion
MSCs are being extensively investigated for use in tissue
regeneration. In the presence of a potent osteogenic inducer,
such as BMP, MSCs can accelerate bone formation and lead
to spine fusion. This can be achieved either by culturing
MSCs in the presence of BMP and then transplanting them35
or by overexpressing the gene encoding for BMP-2 in the
implanted cells. The latter approach has the advantage of a
sustained secretion of BMP in vivo, affecting both host and
the implanted cells, in a synergistic autocrine/paracrine
mechanism.36 We have previously shown that BMP gene-
modified MSCs secrete physiological quantities (nanograms)
of BMP28,34 over a period of few weeks compared to the
mega doses used in rhBMP therapy (milligrams). Thus, the
use of gene-modified MSCs might prevent recently described
toxic side effects and inflammatory response induced by
high doses of BMP11,12. In addition, gene modification could
be applied to freshly isolated, noncultured MSCs37 without
the need for a cell culture phase. The use of noncultured
MSCs could facilitate the translation of this therapeutic ap-
proach to the clinical arena. The present study marks the first
time that the biomechanical properties of spinal fusion in-
duced by injected genetically engineered MSCs have been
evaluated. Before this study, we have only evaluated the
morphometric and histological properties of the newly
formed bone28,38 and the nanomechanical and nanos-
tructural properties of the engineered tissue.26 The biome-
chanical tests that we performed represent a novel
quantitative investigation of fusion integrity that enabled us
to evaluate the quality of the spinal fusion and its clinical
relevance.
Our findings demonstrate that the rigidity of spines fused
using genetically engineered cells is similar to that of spines
fused using bilateral stainless steel fixation across the verte-
bral processes; the MSC/þDOX and FG Only control groups
exhibited significantly less rigidity, similar to those found in
the Native Spine group. These findings show that the spinal
fusion achieved using injections of genetically engineered
MSCs can provide segmental stabilization of vertebrae
without the need for an invasive surgical operation.
The structural properties of de novo bone tissue formation
induced by genetically engineered MSCs were quantified
using mCT. 3D mCT reconstructions of the spines demon-
strated a bridge spanning 3.1 0.6 vertebrae per mouse
FIG. 6. Histological and immunohistochemical analysis of the newly formed bone. Histological analysis showed a fusion
between the newly formed bone mass and the intact vertebra. Immunohistochemistry for b-Gal showed the presence of
genetically engineered MSCs in the newly formed bone. (A) Hematoxylin and eosin standard staining; (B) Masson’s Tri-
chrome bone mass-specific staining; (C) immunohistochemical staining for b-Gal. Boxes show magnification of specific areas
in the section. Arrows represent spinal fusion sites. IV, intact vertebra; NB, new bone; CL, cartilage-like tissue; SC, spinal
cord; BM, bone marrow. Color images available online at www.liebertonline.com/ten.
3684 SHEYN ET AL.
(n¼ 9) and 2.4 0.4 vertebrae per injection (n¼ 9), although
the bone tissue formed along the paraspinal muscle. The
localization of spinal fusion in desired segments may be
easier in a large animal model, because the choice of injection
site in such a model can be more accurately controlled. In
addition, we envision that in a large animal, multiple injec-
tions of stem cells will induce incremental bone tissue for-
mation, increasing control over the site of tissue formation
and spinal fusion.
In this study we also evaluated the relative contribution of
the fused spine segments to the rigidity of the entire spine.
Our findings demonstrated that the largest contribution
came from the fused L3–L5 segment, corresponding to the
site of the MSC injection and correlating to stainless steel pin-
based fusion. When we examined the structural properties of
the new bone formation, which we quantified using mCT, we
found that the newly formed bone had a lower BVD and
BMD than the posterolateral compartment of intact vertebra.
These findings were probably due to the relatively short
period of tissue formation, which is insufficient to create
mature bone that can hold up to the same parameters as
intact bone, which was used as a control (Native Spine
group) in this study. On the other hand, when it comes to the
structural parameters of the newly formed bone mass, such
as DA and average BT, we found values similar to that of
native vertebra. Further, the Conn-Den of new bone mass
was greater than that in the control vertebra ( p< 0.05),
demonstrating that although not completely matured, the
new bone has a branched structure that is sufficiently robust
to enable a stable fusion.
Histological analyses of bone mass performed using
standard H&E and Masson trichrome stains confirmed that
the newly formed mass has typical morphological charac-
teristics of bone, including cortex, trabeculae, and bone
marrow. In addition, several cartilage-like islands were
found inside the new bone formation, which probably rep-
resent cells that have not yet fully differentiated but will do
so later and will contribute to the BVD and the strength of
the tissue and fusion.
An immunohistochemical analysis was performed to de-
tect engineered MSCs within the new bone mass. The assay
showed that the newly formed bone contained cells that
expressed b-Gal. Most of the positively stained cells were
hypertrophic chondrocytes, whereas others were osteocytes
embedded in new bone. Yet, it is hard to determine precisely
using this method how much of the bone tissue was formed
by the implanted cells compared to the contribution of host
cells recruited to the region. However, it is safe to assume
that both donor and host cells contributed to the new bone
formation, given the paracrine action of the rhBMP-2 ex-
pressed by the MSCs, which would activate nearby host cells
to differentiate into osteogenic cells.28
All these findings support and reinforce the value of our
MSC-based treatment as a method of stabilizing vertebrae.
The biomechanical data represent an essential proof of
principle with regard to the functional stability of the fused
vertebrae. Although biomechanical stabilization has been
demonstrated, it is important to note that this approach in-
volves heretrotopic ossification, which is not the current
practice in the clinic today. Therefore, further examination of
this model is needed in larger animal models. These future
experiments will eventually allow us to advance the method
to clinical trials and further evaluate the quality of MSC in-
duced spinal fusion as a potential noninvasive technique for
fixture of spinal vertebrae. We envision that in the future, the
clinical application of this model to posterior and anterior
spinal fusion will include fresh immunoisolated human
MSCs37 and that overexpression of BMP will be achieved via
nonviral gene delivery21,24 of MSCs shortly after their isola-
tion. In summary, we presented here an injectable therapy
for spine fusion that does not involve complex surgical
procedures. In addition, the use of potent osteogenic cells
could potentially replace the use of autografts that result in
comorbidity at the donor site or allografts that have limited
osteoinduction properties.
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